

## On the footsteps of Triadin and its role in skeletal muscle

Claudio F Perez

Claudio F Perez, Department of Anesthesiology, Perioperative and Pain Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, United States

Author contributions: Perez CF solely contributed to this paper. Supported by NIH Grant 5K01AR054818 (to Perez CF) and P01AR47605 (to Allen PD)

Correspondence to: Claudio F Perez, PhD, Department of Anesthesiology, Perioperative and Pain Medicine, Brigham and Women's Hospital, Harvard Medical School, TH-726C, 20 Shattuck Street, Boston, MA 02115,

United States. [cperez@zeus.bwh.harvard.edu](mailto:cperez@zeus.bwh.harvard.edu)

Telephone: +1-617-7326881 Fax: +1-617-7326927

Received: June 23, 2011 Revised: July 29, 2011

Accepted: August 5, 2011

Published online: August 26, 2011

**Key words:** Excitation-contraction coupling; Triadin-null; Calcium release; Ryanodine receptor; FKBP12; Resting calcium

**Peer reviewers:** Sheng-Tao Hou, Professor, Institute for Biological Sciences, National Research Council of Canada, 1200 Montreal Road, Bldg M-54, Ottawa, Ontario, K1A 0R6, Canada; Luca Munaron, PhD, Associate Professor, Department of Animal and Human Biology, University of Torino, Via Accademia Albertina 13, 10123 Torino, Italy

Perez CF. On the footsteps of Triadin and its role in skeletal muscle. *World J Biol Chem* 2011; 2(8): 177-183 Available from: URL: <http://www.wjgnet.com/1949-8454/full/v2/i8/177.htm> DOI: <http://dx.doi.org/10.4331/wjbc.v2.i8.177>

### Abstract

Calcium is a crucial element for striated muscle function. As such, myoplasmic free  $Ca^{2+}$  concentration is delicately regulated through the concerted action of multiple  $Ca^{2+}$  pathways that relay excitation of the plasma membrane to the intracellular contractile machinery. In skeletal muscle, one of these major  $Ca^{2+}$  pathways is  $Ca^{2+}$  release from intracellular  $Ca^{2+}$  stores through type-1 ryanodine receptor/ $Ca^{2+}$  release channels (RyR1), which positions RyR1 in a strategic cross point to regulate  $Ca^{2+}$  homeostasis. This major  $Ca^{2+}$  traffic point appears to be highly sensitive to the intracellular environment, which senses through a plethora of chemical and protein-protein interactions. Among these modulators, perhaps one of the most elusive is Triadin, a muscle-specific protein that is involved in many crucial aspect of muscle function. This family of proteins mediates complex interactions with various  $Ca^{2+}$  modulators and seems poised to be a relevant modulator of  $Ca^{2+}$  signaling in cardiac and skeletal muscles. The purpose of this review is to examine the most recent evidence and current understanding of the role of Triadin in muscle function, in general, with particular emphasis on its contribution to  $Ca^{2+}$  homeostasis.

© 2011 Baishideng. All rights reserved.

### INTRODUCTION

More than two decades after its discovery, and in spite a significant number of studies, our understanding of the role of Triadin in muscle function has remained, for the most part, unclear and elusive. This family of proteins, which are highly abundant and specific to striated muscle, have garnered a significant level of attention fuelled primarily by their ability to interact with the ryanodine receptor (RyR), a  $Ca^{2+}$  release channel that plays a preponderant role in skeletal and cardiac muscle function.

The multiple isoforms of Triadins currently identified in muscle cells seem consistent with the multiplicity of roles credited to these proteins, which include among others, modulation of RyR activity, excitation-contraction (EC) coupling, and  $Ca^{2+}$  homeostasis. The recent development of Triadin-null mouse models have provided us with a critical tool to understand the role of these proteins and have revealed important new insights into the mechanisms that regulate  $Ca^{2+}$  homeostasis in striated muscles.

### PROTEIN HETEROGENEITY AND GENE STRUCTURE

Triadin was originally identified by Caswell *et al*<sup>[1]</sup> and

Kim *et al*<sup>[2]</sup> as a highly enriched 95-kDa protein of the junctional sarcoplasmic reticulum (jSR) in rabbit skeletal muscle. The primary sequence and structure of skeletal Triadin was later deduced from its cDNA sequence, which predicted a 705-amino-acid intrinsic membrane protein containing a short cytoplasmic N terminus, a single membrane-spanning domain, and a long intraluminal C-terminal domain<sup>[3,4]</sup>. Subsequent studies in rabbit hearts identified three unique cardiac Triadin isoforms with molecular mass of 35, 40 and 92 kDa<sup>[5]</sup>. Given that all isoforms, skeletal and cardiac, share identical sequences between amino acids 1-264 but have a unique C-terminal region, it appears that all Triadin proteins are products from alternative splicing of a single Triadin (*Trdn*) gene. Recent sequencing of the whole mouse genome has confirmed this perception (Figure 1). Subsequent studies in other species have revealed that similar tissue-specific patterns of Triadin expression are also present in mouse, canine, rat and human cardiac and skeletal muscle<sup>[6-9]</sup>. A summary of all Triadin genes currently cloned from cardiac and skeletal muscle is presented in Table 1.

Cardiac muscle appears to express a major Triadin isoform of 32 kDa (CT1 or MT1), which is susceptible to glycosylation and migrates as a secondary 38-kDa band<sup>[5,6,10]</sup>. A 92-kDa isoform has also been reported in rabbit and canine hearts but its expression is much less prominent than the 32-38-kDa doublet<sup>[5,6]</sup>. Similarly, it appears that in skeletal muscles Triadin is expressed predominantly as a 95-kDa isoform<sup>[1,3,4,6,8,11-13]</sup>. However, recent studies in rat skeletal muscle have also identified, and cloned, several shorter Triadin isoforms of 32, 49 and 51 kDa (Trisk-32, Trisk-49 and Trisk-51, respectively)<sup>[7,9]</sup>. Using the same antibodies generated against the rat skeletal Triadin, the expression of these shorter isoforms has recently been confirmed in mouse skeletal muscle<sup>[14]</sup>, suggesting that multiplicity of isoforms may be a common feature of skeletal Triadin. Whether or not this multiplicity of Triadins is associated with specific functional roles for each isoform is still unknown<sup>[15,16]</sup>. However, the wide array of Triadin-protein interactions currently reported and the diversity of functional effects directly and indirectly associated with exogenous manipulation of Triadin expression levels seem to support this hypothesis.

## PROTEIN-PROTEIN INTERACTIONS

Direct molecular interactions between Triadin and several protein components of the jSR, including the L-Type Ca<sup>2+</sup> channel (dihydropyridine receptor, DHPR), RyRs and calsequestrin (Csq), among others, have been consistently reported in skeletal and cardiac muscle. As a result of the importance of many of these components for Ca<sup>2+</sup> regulation, it is not surprising that alteration of these interactions has visible functional consequences for Ca<sup>2+</sup> homeostasis.

### DHPR $\alpha_{1S}$

In skeletal muscle, early overlay experiments have sug-

**Table 1** Triadin isoforms cloned from cardiac and skeletal muscle


Species	Cloned	Isoform	Mol. mass (kDa)		Ref.
			Predicted	Observed	
Cardiac muscle					
Rabbit	3	CT1	32	35	[5]
		CT2	34.6	40	[5]
		CT3	75	92	[5]
Canine	2	CT1	30.7	35/40 <sup>1</sup>	[6]
		CT3	64.8	92 <sup>2</sup>	[6]
Mouse	3	MT1	31.4	35/38 <sup>1</sup>	[10]
		MT2	33	35.5	[10]
		MT3	34.3	40	[10]
Skeletal muscle					
Rabbit	1		79.1	94	[4]
Rat	4	Trisk 32	32.1	32	[9]
		Trisk 49	49.5	45	[9]
		Trisk 51	51.3	51	[7]
		Trisk 95	77.2	95	[7]
Canine	1		78.3	95	[6]
Human	3		81.5	117	[8]
		Trisk 51	51.5	51	[13]
		Trisk 95	95	95 <sup>2</sup>	[13]

<sup>1</sup>Glycosylated isoform; <sup>2</sup>Marginally expressed or not detected.

gested that Triadin has structural and functional interactions with both the DHPR  $\alpha_{1S}$  subunit and RyR1<sup>[17,18]</sup>. However, with the elucidation of the primary sequence and topological structure of Triadin<sup>[4,11]</sup>, it has become apparent that the DHPR-Triadin interaction involves intraluminal domains of Triadin that are unlikely to be accessible *in situ*. To date, there has been no new evidence that either supports or rules out direct structural or functional interactions between the cytoplasmic domain of Triadin and the DHPR complex.

### RyRs

Immunohistochemistry studies in adult muscles have localized Triadin at the jSR in the vicinity of RyRs, revealing the close association of these two proteins in both skeletal<sup>[4,19]</sup> and cardiac<sup>[20]</sup> muscles. However, in skeletal muscle, co-localization with RyR1 only involves the 95-kDa isoform of Triadin, because the lower molecular weight isoforms (Trisk-32 and Trisk-49) appear to be segregated to non-jSR regions of the muscle<sup>[9]</sup>. Direct RyR1-Triadin interactions have been confirmed using glutathione-S-transferase/Triadin fusion proteins, which suggest that there is a stable multi-protein complex involving Triadin, RyR1 and the Ca<sup>2+</sup> binding protein Csq<sup>[21]</sup>. More recently, mutagenesis analysis has suggested that the Triadin-binding site of RyR1 may reside within the negatively charged residues Asp<sup>4878</sup>, Asp<sup>4907</sup> and Glu<sup>4908</sup> of RyR1<sup>[22]</sup>. Likewise, the corresponding RyR1-binding site of Triadin has been mapped to amino acids 200-232 within the intraluminal domain<sup>[22]</sup>, a region rich in multiple clusters of alternating Lys and Glu residues, known as KEKE motif. This motif is common to all skeletal and cardiac isoforms of Triadin<sup>[22-24]</sup>. The direct functional effect of Triadin-RyR1 interaction on RyR1 channel activity is discussed below.



**Figure 1 Genomic structure of mouse *Trdn* gene.** A: Schematic representation of mouse Triadin cDNA structure within the context of the Triadin genomic locus according to the Mouse Genomic Informatics (MGI) gene model<sup>[60]</sup>; B: Splicing patterns of Triadin. Exons are shown as boxes and introns as lines. The exon splicing pattern that gives rise to the three cardiac Triadin isoforms currently cloned (MT1, MT2 and MT3) as well as the predicted full-length skeletal isoform (Trdn95) are indicated. Size and number of exon boxes in the genomic locus (blue) are not showed in actual scale.

### Csq and junctin

In addition to binding RyRs, Triadin has been shown to directly interact with Csq and Junctin. Csq, an intra-SR  $\text{Ca}^{2+}$  binding protein is thought to be the main  $\text{Ca}^{2+}$  buffer protein of the SR<sup>[25-27]</sup>, whereas Junctin is an SR integral membrane protein that shares structural and amino acid sequence similarity with Triadin<sup>[10,23,28]</sup>. Currently, there seems to be a consensus that Junctin and Triadin interact directly in the jSR membrane and stabilize a quaternary complex that anchors Csq to the RyR, probably through their shared KEKE motifs<sup>[21,23,29]</sup>. These quaternary complexes have been identified biochemically in both skeletal<sup>[21,30]</sup> and cardiac<sup>[23,24]</sup> muscles.

Based on the large  $\text{Ca}^{2+}$  binding capacity of Csq and its ability to undergo significant conformational changes over the physiological range of intra-SR  $\text{Ca}^{2+}$  concentrations<sup>[27,31]</sup>, Csq has been proposed as an intraluminal  $\text{Ca}^{2+}$  sensor that plays a significant role in the ability of RyRs to sense and respond to changes in SR  $\text{Ca}^{2+}$  content. Even though *in vitro* studies in skeletal muscle using purified proteins have suggested that Csq and RyR1 can engage in direct structural/functional interaction<sup>[32-35]</sup>, it is likely that *in vivo*, this functional crosstalk is primarily mediated through their interaction with Triadin and Junctin<sup>[36-38]</sup>. Even though the use of purified RyR1 in artificial bilayer membrane (BLM) studies to test the role of Triadin and Junctin in intraluminal  $\text{Ca}^{2+}$  regulation of skeletal muscle has recently suggested that Junctin may be the only protein involved in mediating signaling between Csq and RyR1<sup>[38]</sup>, our studies have indicated that this may not be the predominant interaction *in vivo*. Indeed,  $\text{Ca}^{2+}$  imaging studies in Junctin-null mice suggest that, unlike in Triadin-null myotubes that show

significant dysregulation of  $\text{Ca}^{2+}$  homeostasis, Junctin-null myotubes have a nearly wild-type phenotype, with no significant alteration in SR  $\text{Ca}^{2+}$  content or  $[\text{Ca}^{2+}]_{\text{rest}}$  (unpublished data). These results strongly support the idea that Triadin is a key functional component of  $\text{Ca}^{2+}$  homeostasis in skeletal muscle.

### Histidine-rich $\text{Ca}^{2+}$ -binding protein

Histidine-rich  $\text{Ca}^{2+}$ -binding protein (HRC) is a  $\text{Ca}^{2+}$ -binding protein found in small amounts in the SR lumen, and shares many biochemical and structural features with Csq<sup>[39-42]</sup>. Biochemical studies in skeletal muscles have found that HRC can bind to Triadin in a  $\text{Ca}^{2+}$ -sensitive manner through the same KEKE motif involved in the binding of Triadin to Csq<sup>[40,43,44]</sup>. Therefore, it is not unlikely that binding of HRC to Triadin could affect RyR activity by disrupting the Triadin/Junctin/RyR/Csq  $\text{Ca}^{2+}$  release complex. Although the role of HRC in  $\text{Ca}^{2+}$  homeostasis in skeletal muscles is unknown, studies in cardiac cells have suggested that HRC is important for  $\text{Ca}^{2+}$  regulation. In the heart, overexpression of HRC is associated with alteration of both SR  $\text{Ca}^{2+}$  release and contractility, which coincidentally is associated with reduction in Triadin and Junctin expression<sup>[41,45,46]</sup>. Conversely, HRC-null mice exhibit a significant increase in Triadin expression<sup>[47]</sup>. However, because cardiac and skeletal muscles express different isoforms of Triadin, the possibility that disruption of the HRC/Triadin interaction in skeletal muscle results in a different functional outcome than that observed in cardiac tissues should not be ruled out. In this regard, our own studies have indicated that, unlike HRC-null mice in which HRC and Triadin expression seem to be interlocked, in Triadin-null mice, the lack

of Triadin expression does not seem to affect HRC expression levels (unpublished data).

Overall, these studies suggest that Triadin is positioned to engage in meaningful structural/functional interactions with key modulatory components of  $\text{Ca}^{2+}$  release, and thus, seems poised to play a pivotal role in  $\text{Ca}^{2+}$  regulation in muscle cells.

## EC COUPLING

RyR/DHPR interaction is key for EC coupling. Since the early biochemical studies in rabbit skeletal muscle<sup>[1,2,17]</sup> showing that Triadin binds to both DHPR  $\alpha_{1S}$  and RyR1 and the proposed ternary complex between the proteins, there have been many studies that have linked Triadin to EC coupling in skeletal muscles.

Although the direct interaction between Triadin and DHPR  $\alpha_{1S}$  has proven difficult to confirm, the evidence supporting a role for Triadin in modulating depolarization-induced  $\text{Ca}^{2+}$  release has been somewhat consistent. Early stopped-flow studies in triad vesicles have demonstrated that the use of an anti-Triadin antibody significantly inhibited depolarization-induced  $\text{Ca}^{2+}$  release<sup>[48]</sup>, which supports the idea that Triadin may be involved in the functional coupling between DHPR and RyR1. More recently, in a series of functional studies, with overexpression of different isoforms of Triadin in cultured myotubes, it has been shown that Trisk-95, but not Trisk-55, significantly inhibits depolarization-induced  $\text{Ca}^{2+}$  release in rat<sup>[49]</sup> and C2C12<sup>[50]</sup> cells, strengthening the idea that Triadin, in particular the 95-kDa isoform, plays a critical regulatory role in skeletal-type EC coupling. Supporting this line of reasoning, Goonasekera *et al*<sup>[51]</sup> have shown that expression of mutant RyRs that lack Triadin-binding ability in dyspedic myotubes dramatically impairs electrically evoked  $\text{Ca}^{2+}$  transients, nearly ablating skeletal-type EC coupling without noticeable effects on other RyR1 functions. Similarly, Wang *et al*<sup>[52]</sup> have shown that the use of siRNAs to knockdown expression of Triadin in cultured myotubes led to a significant reduction in amplitude of  $\text{K}^{+}$ -induced  $\text{Ca}^{2+}$  transients, suggesting that Triadin may play a role in facilitating depolarization-induced  $\text{Ca}^{2+}$  release. However, with the recent development of Triadin-null mice, the idea of Triadin playing a critical or direct role in skeletal-type EC coupling has been challenged. Indeed, despite the lack of Triadin expression, homozygous Triadin-null (*Trdn*<sup>-/-</sup>) mice do not exhibit embryonic or birth lethality nor demonstrate an obvious gross functional phenotype<sup>[12,14]</sup> as has been reported for dyspedic<sup>[53]</sup> and dysgenic mice<sup>[54,55]</sup>, two other mouse models that bear significant disruption of the EC coupling signaling. Triadin-null skeletal muscles, however, have shown a significant decay in strength that confirms the general thought that Triadins are important modulatory components of skeletal muscle function<sup>[14]</sup>.

Interestingly,  $\text{Ca}^{2+}$  imaging studies in Triadin-null myotubes have revealed that the absence of Triadin expression results in a noticeable reduction in peak amplitude


of depolarization-induced  $\text{Ca}^{2+}$  transients<sup>[12]</sup>. Although, whole-cell patch clamp studies of Triadin-null myotubes have demonstrated that null cells display almost normal bidirectional signaling, with no changes in DHPR  $\text{Ca}^{2+}$  current densities and strong voltage-dependent  $\text{Ca}^{2+}$  release activity, they do have a moderate reduction in voltage-dependent  $\text{Ca}^{2+}$  release amplitude, and therefore, reduced orthograde signaling<sup>[56]</sup>.

Triadin-null myotubes also display a significant alteration of the overall  $\text{Ca}^{2+}$  homeostasis driven primarily, but not exclusively, by the disruption of the RyR1/FKBP12 interaction<sup>[57]</sup>. Overexpression of FKBP12.6 can overcome this faulty interaction and almost completely reverse the effects of lack of Triadin expression on  $\text{Ca}^{2+}$  homeostasis. More importantly, overexpression of FKBP12.6 also is sufficient to erase all of the differences in depolarization-induced  $\text{Ca}^{2+}$  release observed between wild-type and Triadin-null myotubes<sup>[56]</sup>. The full restoration of EC coupling signals of Triadin-null myotubes by FKBP12.6 strongly suggests that the effects of Triadin on the orthograde signal are not directly but indirectly mediated by its side effects on the RyR1/FKBP12 interaction. Thus, further supporting the idea that skeletal Triadins are not involved in the bidirectional coupling between DHPR and RyR1.

## MYOPLASMIC $\text{Ca}^{2+}$ REGULATION

The well-documented interaction between Triadin and RyR1 has a significant impact on the  $\text{Ca}^{2+}$  channel behavior, and consequently,  $\text{Ca}^{2+}$  regulation in skeletal muscle cells. The first indication of a direct effect of Triadin on RyR1 function came from studies of Ohkura *et al*<sup>[35]</sup>, who have reported that purified Triadin has an inhibitory effect on both <sup>3</sup>H-ryanodine binding to solubilized RyR1s, and on  $\text{Ca}^{2+}$  channel activity of purified RyR1 fused into BLMs. At the same time, Groh *et al*<sup>[58]</sup> have shown that a peptide containing a short fragment of the cytoplasmic domain of Triadin not only reduced the open probability of native and purified RyR1 channels in BLMs, but also inhibited the overall  $\text{Ca}^{2+}$  release from SR vesicles, identifying one of the first discrete domains of Triadin directly involved in a functional interaction with RyR1.

Our studies on native RyR1 channels reconstituted from Triadin-null skeletal muscles have revealed that the absence of Triadin significantly increases sub-conductance states of RyR channels, which in turn result in elevation of overall open probability. This enhanced channel activity seems to be directly associated with loss of FKBP12 binding capacity of RyR1, because the addition of exogenous FKBP12.6, that has a higher affinity for RyR1 than FKBP12, significantly reduces channel activity<sup>[57]</sup>. However, in a recent study, Wei *et al*<sup>[38]</sup> have found that, unlike previous studies, addition of purified skeletal Triadin had instead an activating effect on the channel activity of purified RyR1 fused into BLMs. It is still unclear whether these differences in functional effect account for differences in experimental protocols or actual functional



**Figure 2** Proposed model of  $\text{Ca}^{2+}$  regulation by Triadin in wild-type and Triadin-null skeletal muscle. Lack of Triadin binding to type-1 ryanodine receptor (RyR1) indirectly affects FKBP12/RyR1 interaction causing, on the one hand, an increase in RyR1 channel gating and, on the other hand, a weakening of the DHPR $\alpha_1$ /RyR1 orthograde signaling. Dysregulation of RyR1 activity of Triadin-null cells leads to enhanced SR  $\text{Ca}^{2+}$  leakage and subsequent reduction in SR  $\text{Ca}^{2+}$  content. In addition, lack of Triadin expression activates  $\text{Ca}^{2+}$  entry pathways that are both store-dependent and store-independent (sensitive to TRPC/Orai-1 inhibitors).  $\text{Ca}^{2+}$  entry and SR  $\text{Ca}^{2+}$  leakage could contribute independently to elevate myoplasmic  $[\text{Ca}^{2+}]_{\text{rest}}$ .

differences in Triadin-binding sites at the intraluminal and cytoplasmic domain of RyR1. However, what all these reports seem to agree on is the idea that changes in Triadin expression result in modulation of RyR1  $\text{Ca}^{2+}$  channel activity.

Consistent with the enhanced basal activity observed in RyR channels from Triadin-null muscles, *Trdn*<sup>-/-</sup> myotubes are characterized by reduced  $\text{Ca}^{2+}$  release response to caffeine<sup>[12,14,57]</sup> and the sarcoplasmic/endoplasmic reticulum calcium pump inhibitor thapsigargin<sup>[12,14]</sup>, both suggestive of alterations in the SR  $\text{Ca}^{2+}$  content. Similar observations have been reported in Triadin-knockdown myotubes, where in addition to reduced SR  $\text{Ca}^{2+}$  load, there is an increased frequency in  $\text{Ca}^{2+}$  spark activity<sup>[50]</sup>. In agreement with these reports, reduced caffeine-induced  $\text{Ca}^{2+}$  release responses are also observed in dyspedic myotubes expressing Triadin-binding-deficient RyRs<sup>[51,59]</sup>. Overall, these results seem to support the idea that loss of Triadin expression leads to loss of negative regulation on RyR channels, which in turn, results in enhanced SR  $\text{Ca}^{2+}$  leakage. Accordingly, overexpression of Triadin in skeletal myotubes, a condition that should increase the negative regulation on RyR1 and suppress SR  $\text{Ca}^{2+}$  leakage, appears not to have a detrimental effect on caffeine-induced  $\text{Ca}^{2+}$  release and SR  $\text{Ca}^{2+}$  load<sup>[49,50]</sup>.

Myotubes and adult muscle fibers from Triadin-null mice also show chronically elevated  $[\text{Ca}^{2+}]_{\text{rest}}$ <sup>[12,50,57]</sup>. This elevated resting myoplasmic  $[\text{Ca}^{2+}]_{\text{rest}}$  is partially reversed by inhibitors of RyR1 activity (ryanodine and FKBP12.6) and RyR1 leakage (bastadin-5). Similar effects have been observed with  $\text{Ca}^{2+}$  entry blockers ( $\text{Cd}^{2+}$  and  $\text{La}^{3+}$ ) and

TRPC/Orai-1 blockers (2-APB and BTP-2)<sup>[57]</sup>. This pharmacological profile is consistent with the idea that elevated resting  $\text{Ca}^{2+}$  in Triadin-null muscle cells involves both RyR-mediated SR  $\text{Ca}^{2+}$  leakage and enhanced extracellular  $\text{Ca}^{2+}$  entry at rest<sup>[57]</sup>. The effect of 2-APB and BTP-2 on  $[\text{Ca}^{2+}]_{\text{rest}}$  in addition to the elevated intracellular  $[\text{Na}^+]$  observed in Triadin-null cells (unpublished data) strongly suggests that the extracellular  $\text{Ca}^{2+}$  entry pathway activated by the lack of Triadin may be, at least partially, mediated by TRP channels or Orai-1.

In summary, the current accumulated data from Triadin-null muscle cells support the molecular model depicted in Figure 2 in which the lack of Triadin expression significantly destabilizes the FKBP12/RyR1 interaction, causing increased basal activity of RyR  $\text{Ca}^{2+}$  channels. This in turn results in increased SR calcium leakage, which contributes to elevate the myoplasmic resting free  $\text{Ca}^{2+}$ . On the other hand, this increased  $\text{Ca}^{2+}$  leakage leads to partial depletion of SR calcium stores, which drives TRPC- and/or Orai-1-mediated  $\text{Ca}^{2+}$  entry, further contributing to elevation of resting  $\text{Ca}^{2+}$ .

Although many questions remain, a clear picture of Triadins playing a relevant modulatory role in  $\text{Ca}^{2+}$  homeostasis of skeletal muscle has emerged. Triadin control of RyR  $\text{Ca}^{2+}$  channel activity has the potential to unravel a cascade of events that can ultimately adjust  $\text{Ca}^{2+}$  flux equilibrium in muscle cells, resulting in permanent modification of  $[\text{Ca}^{2+}]_{\text{rest}}$ . Hence, it appears that although not directly involved in  $\text{Ca}^{2+}$  transport Triadins may contribute a significant role to fine-tuning  $\text{Ca}^{2+}$  homeostasis in skeletal muscles.

## ACKNOWLEDGMENTS

The author wishes to acknowledge Dr. Paul D Allen for help in editing the manuscript and for financial support in creating the Triadin-null mouse.

## REFERENCES

- 1 Caswell AH, Brandt NR, Brunschwig JP, Purkerson S. Localization and partial characterization of the oligomeric disulfide-linked molecular weight 95,000 protein (triadin) which binds the ryanodine and dihydropyridine receptors in skeletal muscle triadic vesicles. *Biochemistry* 1991; **30**: 7507-7513
- 2 Kim KC, Caswell AH, Talvenheimo JA, Brandt NR. Isolation of a terminal cisterna protein which may link the dihydropyridine receptor to the junctional foot protein in skeletal muscle. *Biochemistry* 1990; **29**: 9281-9289
- 3 Knudson CM, Stang KK, Jorgensen AO, Campbell KP. Biochemical characterization of ultrastructural localization of a major junctional sarcoplasmic reticulum glycoprotein (triadin). *J Biol Chem* 1993; **268**: 12637-12645
- 4 Knudson CM, Stang KK, Moomaw CR, Slaughter CA, Campbell KP. Primary structure and topological analysis of a skeletal muscle-specific junctional sarcoplasmic reticulum glycoprotein (triadin). *J Biol Chem* 1993; **268**: 12646-12654
- 5 Guo W, Jorgensen AO, Jones LR, Campbell KP. Biochemical characterization and molecular cloning of cardiac triadin. *J Biol Chem* 1996; **271**: 458-465
- 6 Kobayashi YM, Jones LR. Identification of triadin 1 as the predominant triadin isoform expressed in mammalian myocardium. *J Biol Chem* 1999; **274**: 28660-28668
- 7 Marty I, Thevenon D, Scotto C, Groh S, Sainnier S, Robert M, Grunwald D, Villaz M. Cloning and characterization of a new isoform of skeletal muscle triadin. *J Biol Chem* 2000; **275**: 8206-8212
- 8 Taske NL, Eyre HJ, O'Brien RO, Sutherland GR, Denborough MA, Foster PS. Molecular cloning of the cDNA encoding human skeletal muscle triadin and its localisation to chromosome 6q22-6q23. *Eur J Biochem* 1995; **233**: 258-265
- 9 Vassilopoulos S, Thevenon D, Rezgou SS, Brocard J, Chapel A, Lacampagne A, Lunardi J, Dewaard M, Marty I. Triadins are not triad-specific proteins: two new skeletal muscle triadins possibly involved in the architecture of sarcoplasmic reticulum. *J Biol Chem* 2005; **280**: 28601-28609
- 10 Hong CS, Ji JH, Kim JP, Jung DH, Kim DH. Molecular cloning and characterization of mouse cardiac triadin isoforms. *Gene* 2001; **278**: 193-199
- 11 Marty I, Robert M, Ronjat M, Bally I, Arlaud G, Villaz M. Localization of the N-terminal and C-terminal ends of triadin with respect to the sarcoplasmic reticulum membrane of rabbit skeletal muscle. *Biochem J* 1995; **307** (Pt 3): 769-774
- 12 Shen X, Franzini-Armstrong C, Lopez JR, Jones LR, Kobayashi YM, Wang Y, Kerrick WG, Caswell AH, Potter JD, Miller T, Allen PD, Perez CF. Triadins modulate intracellular Ca(2+) homeostasis but are not essential for excitation-contraction coupling in skeletal muscle. *J Biol Chem* 2007; **282**: 37864-37874
- 13 Thevenon D, Smida-Rezgou S, Chevessier F, Groh S, Henry-Berger J, Beatriz Romero N, Villaz M, DeWaard M, Marty I. Human skeletal muscle triadin: gene organization and cloning of the major isoform, Trisk 51. *Biochem Biophys Res Commun* 2003; **303**: 669-675
- 14 Oddoux S, Brocard J, Schweitzer A, Szentesi P, Giannesini B, Brocard J, Fauré J, Pernet-Gallay K, Bendahan D, Lunardi J, Csernoch L, Marty I. Triadin deletion induces impaired skeletal muscle function. *J Biol Chem* 2009; **284**: 34918-34929
- 15 Allen PD. Triadin, not essential, but useful. *J Physiol* 2009; **587**: 3123-3124
- 16 Marty I, Fauré J, Fourest-Lieuvain A, Vassilopoulos S, Oddoux S, Brocard J. Triadin: what possible function 20 years later? *J Physiol* 2009; **587**: 3117-3121
- 17 Brandt NR, Caswell AH, Wen SR, Talvenheimo JA. Molecular interactions of the junctional foot protein and dihydropyridine receptor in skeletal muscle triads. *J Membr Biol* 1990; **113**: 237-251
- 18 Fan H, Brandt NR, Peng M, Schwartz A, Caswell AH. Binding sites of monoclonal antibodies and dihydropyridine receptor alpha 1 subunit cytoplasmic II-III loop on skeletal muscle triadin fusion peptides. *Biochemistry* 1995; **34**: 14893-14901
- 19 Carl SL, Felix K, Caswell AH, Brandt NR, Brunschwig JP, Meissner G, Ferguson DG. Immunolocalization of triadin, DHP receptors, and ryanodine receptors in adult and developing skeletal muscle of rats. *Muscle Nerve* 1995; **18**: 1232-1243
- 20 Carl SL, Felix K, Caswell AH, Brandt NR, Ball WJ, Vaghy PL, Meissner G, Ferguson DG. Immunolocalization of sarcolemmal dihydropyridine receptor and sarcoplasmic reticular triadin and ryanodine receptor in rabbit ventricle and atrium. *J Cell Biol* 1995; **129**: 673-682
- 21 Guo W, Campbell KP. Association of triadin with the ryanodine receptor and calsequestrin in the lumen of the sarcoplasmic reticulum. *J Biol Chem* 1995; **270**: 9027-9030
- 22 Lee JM, Rho SH, Shin DW, Cho C, Park WJ, Eom SH, Ma J, Kim DH. Negatively charged amino acids within the intraluminal loop of ryanodine receptor are involved in the interaction with triadin. *J Biol Chem* 2004; **279**: 6994-7000
- 23 Zhang L, Kelley J, Schmeisser G, Kobayashi YM, Jones LR. Complex formation between junctin, triadin, calsequestrin, and the ryanodine receptor. Proteins of the cardiac junctional sarcoplasmic reticulum membrane. *J Biol Chem* 1997; **272**: 23389-23397
- 24 Kobayashi YM, Alseikhan BA, Jones LR. Localization and characterization of the calsequestrin-binding domain of triadin 1. Evidence for a charged beta-strand in mediating the protein-protein interaction. *J Biol Chem* 2000; **275**: 17639-17646
- 25 MacLennan DH, Wong PT. Isolation of a calcium-sequestering protein from sarcoplasmic reticulum. *Proc Natl Acad Sci USA* 1971; **68**: 1231-1235
- 26 Meissner G, Conner GE, Fleischer S. Isolation of sarcoplasmic reticulum by zonal centrifugation and purification of Ca<sup>2+</sup>-pump and Ca<sup>2+</sup>-binding proteins. *Biochim Biophys Acta* 1973; **298**: 246-269
- 27 Ikemoto N, Ronjat M, Mészáros LG, Koshita M. Postulated role of calsequestrin in the regulation of calcium release from sarcoplasmic reticulum. *Biochemistry* 1989; **28**: 6764-6771
- 28 Jones LR, Zhang L, Sanborn K, Jorgensen AO, Kelley J. Purification, primary structure, and immunological characterization of the 26-kDa calsequestrin binding protein (junctin) from cardiac junctional sarcoplasmic reticulum. *J Biol Chem* 1995; **270**: 30787-30796
- 29 Liu G, Pessah IN. Molecular interaction between ryanodine receptor and glycoprotein triadin involves redox cycling of functionally important hyperreactive sulfhydryls. *J Biol Chem* 1994; **269**: 33028-33034
- 30 Glover L, Culligan K, Cala S, Mulvey C, Ohlendieck K. Calsequestrin binds to monomeric and complexed forms of key calcium-handling proteins in native sarcoplasmic reticulum membranes from rabbit skeletal muscle. *Biochim Biophys Acta* 2001; **1515**: 120-132
- 31 Hidalgo C, Donoso P, Rodriguez PH. Protons induce calsequestrin conformational changes. *Biophys J* 1996; **71**: 2130-2137
- 32 Szegedi C, Sárközi S, Herzog A, Jóna I, Varsányi M. Calsequestrin: more than 'only' a luminal Ca<sup>2+</sup> buffer inside the sarcoplasmic reticulum. *Biochem J* 1999; **337** (Pt 1): 19-22
- 33 Herzog A, Szegedi C, Jóna I, Herberg FW, Varsányi M. Surface plasmon resonance studies prove the interaction of

- skeletal muscle sarcoplasmic reticular Ca(2+) release channel/ryanodine receptor with calsequestrin. *FEBS Lett* 2000; **472**: 73-77
- 34 **Beard NA**, Sakowska MM, Dulhunty AF, Laver DR. Calsequestrin is an inhibitor of skeletal muscle ryanodine receptor calcium release channels. *Biophys J* 2002; **82**: 310-320
- 35 **Ohkura M**, Furukawa K, Fujimori H, Kuruma A, Kawano S, Hiraoka M, Kuniyasu A, Nakayama H, Ohizumi Y. Dual regulation of the skeletal muscle ryanodine receptor by triadin and calsequestrin. *Biochemistry* 1998; **37**: 12987-12993
- 36 **Beard NA**, Casarotto MG, Wei L, Varsányi M, Laver DR, Dulhunty AF. Regulation of ryanodine receptors by calsequestrin: effect of high luminal Ca2+ and phosphorylation. *Biophys J* 2005; **88**: 3444-3454
- 37 **Beard NA**, Wei L, Cheung SN, Kimura T, Varsányi M, Dulhunty AF. Phosphorylation of skeletal muscle calsequestrin enhances its Ca2+ binding capacity and promotes its association with junctin. *Cell Calcium* 2008; **44**: 363-373
- 38 **Wei L**, Gallant EM, Dulhunty AF, Beard NA. Junctin and triadin each activate skeletal ryanodine receptors but junctin alone mediates functional interactions with calsequestrin. *Int J Biochem Cell Biol* 2009; **41**: 2214-2224
- 39 **Hofmann SL**, Brown MS, Lee E, Pathak RK, Anderson RG, Goldstein JL. Purification of a sarcoplasmic reticulum protein that binds Ca2+ and plasma lipoproteins. *J Biol Chem* 1989; **264**: 8260-8270
- 40 **Lee HG**, Kang H, Kim DH, Park WJ. Interaction of HRC (histidine-rich Ca(2+)-binding protein) and triadin in the lumen of sarcoplasmic reticulum. *J Biol Chem* 2001; **276**: 39533-39538
- 41 **Gregory KN**, Ginsburg KS, Bodi I, Hahn H, Marreez YM, Song Q, Padmanabhan PA, Mitton BA, Waggoner JR, Del Monte F, Park WJ, Dorn GW, Bers DM, Kranias EG. Histidine-rich Ca binding protein: a regulator of sarcoplasmic reticulum calcium sequestration and cardiac function. *J Mol Cell Cardiol* 2006; **40**: 653-665
- 42 **Arvanitis DA**, Vafiadaki E, Fan GC, Mitton BA, Gregory KN, Del Monte F, Kontogianni-Konstantopoulos A, Sanoudou D, Kranias EG. Histidine-rich Ca-binding protein interacts with sarcoplasmic reticulum Ca-ATPase. *Am J Physiol Heart Circ Physiol* 2007; **293**: H1581-H1589
- 43 **Sacchetto R**, Turcato F, Damiani E, Margreth A. Interaction of triadin with histidine-rich Ca(2+)-binding protein at the triadic junction in skeletal muscle fibers. *J Muscle Res Cell Motil* 1999; **20**: 403-415
- 44 **Sacchetto R**, Damiani E, Turcato F, Nori A, Margreth A. Ca(2+)-dependent interaction of triadin with histidine-rich Ca(2+)-binding protein carboxyl-terminal region. *Biochem Biophys Res Commun* 2001; **289**: 1125-1134
- 45 **Fan GC**, Gregory KN, Zhao W, Park WJ, Kranias EG. Regulation of myocardial function by histidine-rich, calcium-binding protein. *Am J Physiol Heart Circ Physiol* 2004; **287**: H1705-H1711
- 46 **Arvanitis DA**, Vafiadaki E, Sanoudou D, Kranias EG. Histidine-rich calcium binding protein: the new regulator of sarcoplasmic reticulum calcium cycling. *J Mol Cell Cardiol* 2011; **50**: 43-49
- 47 **Jaehnig EJ**, Heidt AB, Greene SB, Cornelissen I, Black BL. Increased susceptibility to isoproterenol-induced cardiac hypertrophy and impaired weight gain in mice lacking the histidine-rich calcium-binding protein. *Mol Cell Biol* 2006; **26**: 9315-9326
- 48 **Brandt NR**, Caswell AH, Brunschwig JP, Kang JJ, Antoniu B, Ikemoto N. Effects of anti-triadin antibody on Ca2+ release from sarcoplasmic reticulum. *FEBS Lett* 1992; **299**: 57-59
- 49 **Rezgui SS**, Vassilopoulos S, Brocard J, Platel JC, Bouron A, Arnoult C, Oddoux S, Garcia L, De Waard M, Marty I. Triadin (Trisk 95) overexpression blocks excitation-contraction coupling in rat skeletal myotubes. *J Biol Chem* 2005; **280**: 39302-39308
- 50 **Fodor J**, Gönczi M, Sztretye M, Dienes B, Oláh T, Szabó L, Csoma E, Szentesi P, Szigeti GP, Marty I, Csernoch L. Altered expression of triadin 95 causes parallel changes in localized Ca2+ release events and global Ca2+ signals in skeletal muscle cells in culture. *J Physiol* 2008; **586**: 5803-5818
- 51 **Goonasekera SA**, Beard NA, Groom L, Kimura T, Lyfenko AD, Rosenfeld A, Marty I, Dulhunty AF, Dirksen RT. Triadin binding to the C-terminal luminal loop of the ryanodine receptor is important for skeletal muscle excitation contraction coupling. *J Gen Physiol* 2007; **130**: 365-378
- 52 **Wang Y**, Li X, Duan H, Fulton TR, Eu JP, Meissner G. Altered stored calcium release in skeletal myotubes deficient of triadin and junctin. *Cell Calcium* 2009; **45**: 29-37
- 53 **Takeshima H**, Iino M, Takekura H, Nishi M, Kuno J, Minowa O, Takano H, Noda T. Excitation-contraction uncoupling and muscular degeneration in mice lacking functional skeletal muscle ryanodine-receptor gene. *Nature* 1994; **369**: 556-559
- 54 **Beam KG**, Knudson CM, Powell JA. A lethal mutation in mice eliminates the slow calcium current in skeletal muscle cells. *Nature* 1986; **320**: 168-170
- 55 **Tanabe T**, Beam KG, Powell JA, Numa S. Restoration of excitation-contraction coupling and slow calcium current in dysgenic muscle by dihydropyridine receptor complementary DNA. *Nature* 1988; **336**: 134-139
- 56 **Eltit JM**, Szpyt J, Li H, Allen PD, Perez CF. Reduced gain of excitation-contraction coupling in triadin-null myotubes is mediated by the disruption of FKBP12/RyR1 interaction. *Cell Calcium* 2011; **49**: 128-135
- 57 **Eltit JM**, Feng W, Lopez JR, Padilla IT, Pessah IN, Molinski TF, Fruen BR, Allen PD, Perez CF. Ablation of skeletal muscle triadin impairs FKBP12/RyR1 channel interactions essential for maintaining resting cytoplasmic Ca2+. *J Biol Chem* 2010; **285**: 38453-38462
- 58 **Groh S**, Marty I, Ottolia M, Prestipino G, Chapel A, Villaz M, Ronjat M. Functional interaction of the cytoplasmic domain of triadin with the skeletal ryanodine receptor. *J Biol Chem* 1999; **274**: 12278-12283
- 59 **Lee EH**, Song DW, Lee JM, Meissner G, Allen PD, Kim do H. Occurrence of atypical Ca2+ transients in triadin-binding deficient-RYR1 mutants. *Biochem Biophys Res Commun* 2006; **351**: 909-914
- 60 **Blake JA**, Bult CJ, Kadin JA, Richardson JE, Eppig JT. The Mouse Genome Database (MGD): premier model organism resource for mammalian genomics and genetics. *Nucleic Acids Res* 2011; **39**: D842-D848

S- Editor Cheng JX L- Editor Kerr C E- Editor Zheng XM